Versant Venture Capital VI, L.P. sold $7.4M of Monte Rosa Therapeutics (GLUE)

Executed Sep 20 2024, disclosed Sep 24 2024, 4 days later.

Value, as filed

$7.4M

1,132,566 sh × $6.53

Executed

Sep 20 2024

the trade date, as filed

Disclosed

Sep 24 2024

4 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

VP Versant Venture Capital VI, L.P. 10% owner profile →

Versant Venture Capital VI, L.P. (10% owner) filed 4 Form 4 reports as a reporting entity in the past 24 months (0 purchases, 4 sales), most often in Monte Rosa Therapeutics, Inc. (GLUE). The largest single filing was $10.3M of LENZ (260,713 sh across 4 lots, as filed), executed Aug 15 2025.

The name

GLUE

Monte Rosa Therapeutics, Inc. GLUE · Healthcare · 17 filings in 24 months ticker →

Healthcare · Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicin…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Versant Venture Capital VI, L.P. in GLUE

GLUESALE Monte Rosa Therapeutics, Inc. $1.5M
157,895 sh across 3 lots
Exec Oct 28 2024
Filed Oct 30 2024 · 5:30 PM ET